HB1801 is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. The lead sponsor is Shanghai JMT-Bio Inc.. Registered phase: Phase 3. Conditions studied include Resectable HER2-positive Breast Cancer; Early or Locally Advanced HER2-positive Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (ClinicalTrials.gov ↗) Resectable HER2-positive Breast Cancer |
Phase 3 | Recruiting |
| NCT06747338 | A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer (ClinicalTrials.gov ↗) Early or Locally Advanced HER2-positive Breast Cancer |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Resectable HER2-positive Breast Cancer | 1 |
| Early or Locally Advanced HER2-positive Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai JMT-Bio Inc. | 2 |
| Register | HB1801 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HB1801 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HB1801 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.